Oncular™

Fast Monitoring Answers, Powered by Oncobit’s Proprietary ctDNA Platform

Overview

Uveal melanoma (UM) is the most common primary intraocular cancer in adults. Despite adequate control of the primary tumor, up to 50% of patients eventually develop metastatic uveal melanoma.1

Traditional surveillance relies heavily on imaging, which may not fully reflect molecular disease activity or predict early treatment response.

Circulating tumor DNA in the blood is correlated with tumor burden and can be assessed in a non-invasive manner through a simple blood draw. By applying a highly sensitive method such as digital PCR, key driver mutations in GNAQ and GNA11, which are present in the vast majority of metastatic uveal melanoma tumors, can be analyzed to enable detection of metastatic disease and real-time monitoring of treatment response.2

50%

~50% of uveal melanoma patients develop metastatic disease4

Uveal melanoma is a rare form of melanoma, accounting for only about 5% of all cases

~1 YEAR

The development of tumors spreading from the eye to other organs in UM patients is associated with an overall survival of approximately one to two years, on average5

Clinical Utility

Earlier Detection of Progression 

  • In metastatic UM, ctDNA rise may precede radiologic progression in some patients.3
  • This lead time advantage supports ctDNA as a powerful complement to imaging in detecting early molecular progression.3

Quantitative Monitoring of Treatment Response

  • ctDNA levels correlate directly with metastatic tumor burden and liver involvement.3
  • Decreasing ctDNA aligns with treatment response (CR/PR), while rising ctDNA is correlated with progression (PD), enabling clinicians to track therapeutic benefit in near real time.3

Complement to Imaging

  • Imaging can underestimate treatment benefit in metastatic UM, especially in immunotherapy settings, where radiologic response does not reliably predict survival.4
  • ctDNA offers a biologically grounded biomarker that enhances clinical confidence when imaging remains unchanged or ambiguous.3,4

Clinical Pathway

Select a Step to Learn More

Behind Oncobit’s Technology

Oncular™ brings Oncobit’s proprietary platform for personalized cancer monitoring to physicians nationwide, enabling real‑time, quantitative assessment of circulating tumor DNA (ctDNA) from a simple blood draw. Designed to complement conventional imaging approaches, the assay provides precise insights into disease dynamics, supporting informed patient management across the care continuum.

Provider Test Kit Request Form

All fields required unless otherwise noted.
The NPI number of the authorizing physician is required to order the test.
Name

Your Order

Please select the quantity you would like to order:
Contact Request
Agreement Review

To learn how TrilliumBiO, the certified clinical laboratory that will perform the testing on the patient samples, will use, disclose and protect the patient data you provide as part of ordering the lab test, please review Trillium's HIPAA Notice of Privacy Practices. While the aPAP ClearPath™ testing program is sponsored by Savara Inc., testing is performed by TrilliumBiO, a CLIA-certified laboratory.​ Savara receives de-identified patient data from this program, but at no time does Savara receive patient-identifiable information. Additionally, Savara will not receive any contact information about the ordering healthcare professional.​Testing can only be ordered by healthcare professionals in the U.S. for patients that meet certain eligibility criteria.​ Use of the test and results should in no way influence or interference with the healthcare professional’s independent clinical judgment or how to manage or what therapy to treat with.​The healthcare professional, in consultation with the patient, should consider all potential management options. Healthcare professionals and patients who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any Savara product.

*These assays were developed and their performance characteristics determined by TrilliumBiO based on Oncobit-developed digital PCR reagents and software technology. They have not been cleared or approved by the U.S. Food and Drug Administration.

References: 1. Damato B, et al. Uveal melanoma: epidemiology, metastatic risk, and outcomes. British Journal of Cancer, 2022. https://www.nature.com/articles/s41416-022-01723-8 2.Bustamante P et al. Circulating tumor DNA tracking through driver mutations as a liquid biopsy–based biomarker for uveal melanoma. JECCR, 2021. https://link.springer.com/article/10.1186/s13046-021-01984-w 3. Park JJ et al. Circulating Tumor DNA Reflects Uveal Melanoma Tumor Burden and Treatment Response. Cancers, 2021. https://pubmed.ncbi.nlm.nih.gov/33917514/ 4.Rodrigues T et al. Prospective ctDNA monitoring identifies molecular response and predicts survival with Tebentafusp. Nat. Communications, 2024. https://www.nature.com/articles/s41467-024-53145-0? 5.Rogala P, et al. Current treatment standards for metastatic uveal melanoma. Cancers (Basel), 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC12896752/